[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100601687":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":27,"centralContacts":32,"locations":10,"responsibleParty":38,"collaborators":41,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":10,"eligibilityCriteria":54,"healthyVolunteers":50,"sex":55,"minAge":10,"maxAge":10,"enrollmentInfo":56,"targetDuration":10,"studyType":59,"phases":10,"briefSummary":60,"conditions":61,"keywords":64,"overallStatus":66,"whyStopped":10,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":10},{"fullName":5,"class":6},"Peking University People's Hospital","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Retrospective cohort",null,"Patients whose first visit to our institution and the termination of follow-up both occurred before the opening of this study will contribute to the retrospective cohort.",[13],"Other: immune reconstitution",{"label":15,"type":10,"description":16,"interventionNames":17},"Prospective cohort","Patients whose first visit to our institution occur after the opening of this study will contribute to the prospective cohort.",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Retrospective\u002FProspective cohort","Patients whose first visit to our institution occurred before the opening of this study and whose follow-up will terminate after the opening of this study will contribute to the ambispective cohort.",[13],[23],{"type":6,"name":24,"description":25,"armGroupLabels":26,"otherNames":10},"immune reconstitution","Detection of immune reconstitution in peripheral blood of patients by flow cytometry at 30-day intervals for 180 days post-transplantation.",[15,9,19],[28],{"name":29,"affiliation":30,"role":31},"Xiao-Hui Zhang, MD","Peking University Institute of Hematology, Peking University People's Hospital","PRINCIPAL_INVESTIGATOR",[33],{"name":34,"role":35,"phone":36,"phoneExt":10,"email":37},"Mengtong Zang, MD","CONTACT","18744579871","zangztong@163.com",{"type":31,"investigatorFullName":39,"investigatorTitle":40,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Xiao Hui Zhang","Vice President of Peking University Institute of Hematology Affiliation: Peking University People's Hospital",[42,44,46],{"name":43,"class":6},"The First Hospital of Jilin University",{"name":45,"class":6},"960th Hospital of Joint Logistics Support Force of People's Liberation Army of China",{"name":47,"class":6},"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","100601687","the-kinetics-profiling-of-immune-reconstitution-and-clinical-outcomes-100601687",false,"NCT07113730","The Kinetics Profiling of Immune Reconstitution and Clinical Outcomes","Retrospective and Prospective Study on the Kinetics Profiling of Immune Reconstitution and Clinical Outcomes in CMML Following Allogeneic Hematopoietic Stem Cell Transplantation","Inclusion Criteria:\n\n1. Patients with confirmed diagnosis of CMML following HSCT\n2. Patients treated at Peking University People's Hospital since January 1, 2005\n\nExclusion Criteria:\n\n1. Any condition that may render follow-up data unreliable, including but not limited to severe psychiatric disorders\n2. Patients deemed ineligible for the study by investigators","ALL",{"count":57,"type":58},300,"ESTIMATED","OBSERVATIONAL","Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic malignancy with poor prognosis. Allogeneic hematopoietic stem cell transplantation (HSCT) remains the only potentially curative treatment. Immune reconstitution (IR) is critical for improving HSCT efficacy and quality of life among survivors, yet its dynamic impact on survival and complications like chronic graft-versus-host disease (cGVHD) in CMML is poorly defined. This study aimed to investigate the dynamics of IR following HSCT in patients with CMML and evaluate its impact on post-transplant clinical outcomes.",[62,63],"Chronic Myelomonocytic Leukemia (CMML)","Immune Reconstitution",[62,24,65],"allogeneic hematopoietic stem cell transplantation (allo-HSCT)","NOT_YET_RECRUITING","2025-08-11",{"date":69,"type":70},"2025-08-15","ACTUAL",{"date":72,"type":58},"2025-08-13",{"date":74,"type":58},"2036-07-31",{"name":5,"class":6}]